Opthea Limited · ASX:OPT

Opthea — Circadian Technologies — Investor Presentation (February 2015)

21 slides from Opthea's investor presentation, February 2015

  1. Slide 1: Developing Inhibitors of VEGF-C/VEGF-D

    Developing Inhibitors of VEGF-C/VEGF-D Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin, CEO & MD, [email protected]

  2. Slide 2: Disclaimer

    Disclaimer Investment in Circadian Technologies Limited (‘Circadian’) is subject to investment risk, including possible loss of income and capital invested. Neither Circadian nor any other member company of the Circadian Group guarantees any particular rate of return or performance, nor do they guar

  3. Slide 3: Corporate Summary

    Corporate Summary - Extensive worldwide intellectual property platform in OPT-302 Wet AMD Program: respect of VEGF-C, VEGF-D and VEGFR-3 - Lead compound OPT-302 blocks VEGF-C and VEGF-D Initiation Phase 1 clinical trial: - OPT-302 in development for treatment of wet AMD 2Q15 - Potential in a range o

  4. Slide 4: Financial Position (Unaudited, Feb 2015)

    Financial Position (Unaudited, Feb 2 2015) - Ticker Symbol: ASX: CIR, OTCQX: CKDXY - Share Price: A$0.16 (as at Feb 2 2015) - Total Shares on Issue 148,086,328 Shareholders by Region - New Options on Issue 49,726,669 (6%) New - Market Capitalisation A$23m Zealand (1%) Retail Asia Australian Retail -

  5. Slide 5: Lead Program: OPT-302 for Wet AMD

    Lead Program: OPT-302 for Wet AMD • Lead molecule: – OPT-302 (soluble VEGFR-3, VEGF-C/-D ‘Trap’) • Mechanism: – Blocks VEGF-C and VEGF-D:  Inhibits blood vessel growth  Inhibits vessel leak • Strategy: – To develop OPT-302 for use in combination with existing VEGF-A inhibitors for the treatment of

  6. Slide 6: The normal retina and 'Wet' (neovascular) AMD

    The normal retina and ‘Wet’ (neovascular) AMD Normal Retina ‘Wet’ AMD Choroid 6 Figure: The Angiogenesis Foundation

  7. Slide 7: Wet (neovascular) AMD

    Wet (neovascular) AMD 7 Photo: The Angiogenesis Foundation

  8. Slide 8: Routine Non-Invasive Monitoring Procedures for Disease and Treatment Efficacy

    Routine Non-Invasive Monitoring Procedures for Disease and Treatment Efficacy Eye Chart (Visual Acuity) Retinal Image 8

  9. Slide 9: Routine Non-Invasive Monitoring Procedures for Disease and Treatment Efficacy

    Routine Non-Invasive Monitoring Procedures for Disease and Treatment Efficacy OCT(Optical Coherence Tomography (Fluid, hemorrhage, retinal thickness, retinal detachment) 9

  10. Slide 10: The opportunity for OPT-302: An unmet medical need remains despite anti-VEGF-A therapy

    The opportunity for OPT-302: An unmet medical need remains despite anti-VEGF-A therapy - Wet AMD is the leading cause of blindness in the western world - Estimated >$US5BN p.a. market opportunity in wet AMD in US alone, increasing with ageing population - Only two targeted therapies approved for wet

  11. Slide 11: The Opportunity for OPT-302

    The Opportunity for OPT-302 • Potential to develop as a monotherapy • Combination therapy has the potential to improve clinical outcomes in Wet AMD patients • Visual Acuity • % patients that experience significant vision gain (> 15 letters ETDRS eye chart) • Magnitude of vision gain (Mean change vis

  12. Slide 12: OPT-302 has comparable single-agent and additive activity with Eylea in mouse AMD

    OPT-302 has comparable single-agent and additive activity with Eylea® in mouse AMD Combined inhibition of VEGF-A (Eylea®), VEGF-C and VEGF-D (OPT-302) is more effective than inhibition of VEGF-A alone Control OPT-302 70% 78% 91% EYLEA™ OPT-302 + EYLEA® * * Pairwise comparison: OPT-302 vs Eylea + OPT

  13. Slide 13: Ophthotech and Opthea: Distinct approaches for wet AMD combination therapy

    Ophthotech and Opthea: Distinct approaches for wet AMD combination therapy Control Macugen® Control OPT-302 Fovista® Fovista + Macugen® EYLEA™ OPT-302 + EYLEA® p<0.02 p<0.05 Control Fovista® Macugen® Fovista ® + Macugen® “Macugen®” – targets VEGF-A165 isoform “Fovista®” – aptamer targeting PDGF-b Jo

  14. Slide 14: OPT-302 Clinical Trials in Wet AMD Patients

    OPT-302 Clinical Trials in Wet AMD Patients - Phase 1 and Phase 2A clinical trials will enrol wet AMD patients OPT-302 Wet AMD Program: - Dosed via IVT monthly for 3 to 4 doses - Safety & multiple outcomes to monitor clinical efficacy Initiation Phase 1 clinical trial:  Visual acuity, central retin

  15. Slide 15: OPT-302 Phase 1: Multiple Dose Combination & Monotherapy Study

    OPT-302 Phase 1: Multiple Dose Combination & Monotherapy Study of Safety, PK & Efficacy Primary Analysis after all subjects Long term follow-up to 12 weeks OPT-302 (Dose level 3) complete 4 week DLT Window + Lucentis® (0.5 mg) IVT Q4W x3 subjects complete 12 weeks Primary Analysis after all OPT-302

  16. Slide 16: Phase 2a Efficacy Study: OPT-302 Combination versus anti-VEGF-A Monotherapy

    Phase 2a Efficacy Study: OPT-302 Combination versus anti-VEGF-A Monotherapy (including extension sub-study of OPT-302 ‘Rescue’ therapy for a-VEGF-A “sub-responders”) Add-on OPT-302 ”rescue therapy” for Lucentis ”sub-responders” Primary Analysis at week 16 “Rescue” OPT-302 + Lucentis® (0.5 mg) Lucent

  17. Slide 17: Clinical Advisory Board & Advisors

    Clinical Advisory Board & Advisors - Clinical Advisory Board of internationally recognised and experienced key opinion leaders from Australia and US - Extensive experience in development of novel and FDA approved therapeutics for wet AMD, including Macugen®, Fovista®, Eylea® and Lucentis® Pravin Dug

  18. Slide 18: Listed Ophthalmology Companies in Phase 1-3

    • Listed Ophthalmology Companies in Phase 1-3 $1.4BN PDGF-B aptamer (Phase 3) Wet AMD Market Cap (A$M) Listed Ophthalmology Companies Ph1-3 $807M (Phase 1/2) 1600 a-VEGF-A gene therapy Wet AMD 1400 1200 ROCK inhib., small mol. $493M Glaucoma (Phase 3) 1000 800 Sustained delivery Wet AMD $378M 600 Av

  19. Slide 19: OPT-302: Intellectual Property

    OPT-302: Intellectual Property Summary covering sVEGFR-3 IP for Eye Disease 19

  20. Slide 20: Summary

    Summary - Leader in VEGF-C/D and VEGFR-3 targeting compounds in ophthalmology and oncology - Lead compound OPT-302 is a fully owned asset with development potential for a range of eye diseases - Fully funded through 2017 and Phase 1 and 2A clinical studies in wet AMD patients  Initiating Phase 1 cl

  21. Slide 21: Thank-you

    Thank-you Megan Baldwin , PhD CEO & Managing Director Circadian Technologies (ASX:CIR, OTCQX:CKDXY) [email protected] +61 (0) 447 788 674

Circadian Technologies — Investor Presentation (February 2015) on 6ix